Intent To Grant an Exclusive License for U.S. Government-Owned Invention

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Defense Department of the Army AGENCY: Department of the Army, DoD. ACTION: Notice. SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable biological materials license. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: Mr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) , announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable biological materials license to topical paromomycin formulation for the treatment of Leishmaniasis, to Appili Therapeutics, Inc., having its principal place of business at #21-1344 Summer Street, Halifax, NS B3H0A8, Canada. Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES ). Brenda S. Bowen, Army Federal Register Liaison Officer. [ FR Doc. 2019-07294 Filed 4-11-19; 8:45 am] BILLING CODE 5001-03-P